Long-term follow-up for TAILORx and RxPONDER participants
Part of Cancer, Skin clinical trials.
This study follows patients who took part in earlier breast cancer trials (TAILORx or RxPONDER) to track their health over time and collect tumor samples for research. It’s not testing a new treatment, but helping scientists learn more about breast cancer outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in one of two past breast cancer studies: TAILORx or RxPONDER.
- If you were in TAILORx, your cancer has come back (recurrence) at the same spot, a distant spot, or both.
- If you were in RxPONDER step 2, your cancer has also come back.
- If you were in RxPONDER step 1, your original risk score must have been high (26 to 100).
- You must have leftover tumor tissue available to send in for research.
- You must be able to sign a consent form (or have a family member or legal representative help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with breast cancer and certain lymphomas to understand long-term sexual and reproductive health. It may help researchers better support patients’ body changes and wellness over time during and after treatment.
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
This study collects tumor-related samples from people with invasive breast cancer who are having surgery after treatment before surgery. Researchers use your samples to create lab models (called PDX and organoids) to help study breast cancer and find better future treatments.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This trial studies a standard follow-up treatment plan that combines chemotherapy and radiation after surgery, and it looks for blood/tissue “biomarkers” that predict who benefits most. If you have high-risk breast cancer that didn’t fully disappear after initial (neoadjuvant) chemo, you may be eligible to help guide better future treatment choices.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.